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Abstract
secondary  activation  of  the  endothelin  system  is
thought to be involved in toxic liver injury. this study
tested the hypothesis that dual endothelin-converting
enzyme/neutralendopeptidase blockade mightbe able
to attenuate acute toxic liver injury.
Male sprague-Dawley rats were implanted with sub-
cutaneous minipumps to deliver the novel compound
slv338 (10 mg/kg*d) or vehicle. Four days later they
received  two  intraperitoneal  injections  of  D-galac-
tosamine (1.3 g/kg each) or vehicle at an interval of
12 hours. the animals were sacrificed 48 hours after
the first injection.
Injection  of  D-galactosamine  resulted  in  very  se-
vere liver injury, reflected by strongly elevated plasma
liver enzymes, hepatic necrosis and inflammation, and
a mortality rate of 42.9 %. slv338 treatment did not
show any significant effect on the extent of acute liver
injury as judged from plasma parameters, hepatic his-
tology  and  mortality.  Plasma  measurements  of
slv338  confirmed  adequate  drug  delivery.  Plasma
concentrations of big endothelin-1 and endothelin-1
were significantly elevated in animals with liver injury
(5-fold and 62-fold, respectively). Plasma endothelin-1
was  significantly  correlated  with  several  markers  of
liver injury. slv338 completely prevented the rise of
plasma big endothelin-1 (p<0.05) and markedly atten-
uated the rise of endothelin-1 (p = 0.055).
In conclusion, dual endothelin-converting enzyme /
neutral  endopeptidase  blockade  by  slv338  did  not
significantly attenuate D-galactosamine-induced acute
liver injury, although it largely prevented the activation
of the endothelin system. an evaluation of slv338 in
a less severe model of liver injury would be of inter-
est, since very severe intoxication might not be rele-
vantly amenable to pharmacological interventions.
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IntRoDuctIon
the liver cell damage seen in acute liver failure is not
only due to direct effects of the precipitating drug,
toxin, viral or other cause, but also due to a secondary
release of proinflammatory and cytotoxic mediators
from  activated  kupffer,  stellate,  and  sinusoidal  en-
dothelial cells, thus creating a vicious circle [1, 2]. En-
dothelin (Et) seems to be one of those mediators. as
recently published in this journal by our group and
also reported by others, the Et system is typically ac-
tivated in acute liver failure [3-6]. Et-1 might play a
key role in the pathogenesis of the microcirculatory
disorders associated with acute liver injury by mediat-
ing  sinusoidal  vasoconstriction,  lowering  the  perfu-
sion  rate  and  promoting  leukocyte  adhesion  [7,  8].
Blockade of the activated Et system might provide a
therapeutic option for acute toxic liver injury. Et a
receptor antagonists have been shown to be beneficial
in  experimental  models  of  acute  liver  injury  [5,6].
neutral endopeptidase (nEP) blockade has beneficial
effects in toxic liver cirrhosis [9]. the metalloprotease
endothelin-converting enzyme (EcE)-1 is important
for the production of active Et-1 by cleaving its pre-
cursor big-Et-1 [10]. an upregulation of EcE-1 was
observed in the early phase of toxic liver injury [11].
the present study set out to investigate the therapeu-
tic potential of a dual EcE/nEP blockade, using the
novel compound slv338, in a rat model of D-galac-
tosamine (galn)-induced acute liver injury. galn-in-
duced acute liver injury is an established model for
the investigation of hepatotoxic pathomechanisms [3,
4, 12].
MatERIal anD MEtHoDs
anIMals anD DRug aDMInIstRatIon
the  animal  experiments  were  conducted  in  accor-
dance with local institutional guidelines for the care
and use of laboratory animals. Male sprague-Dawley
rats (250-300 g; crl:cD(sD), charles River, sulzfeld,
germany)  were  maintained  under  controlled  condi-
tions (20 ﾱ 2ﾰc, 12 h light/dark cycle) with free ac-
cess to food and water. animals were divided into 4
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6) Hocher_Umbruchvorlage  03.06.11  17:21  Seite 275groups: controls (con; n = 9), controls with slv338
treatment  (con+slv;  n  =  9),  D-galactosamine 
(galn;  n  =  20)  and  D-galactosamine  with  slv338
treatment (galn+slv; n = 20). slv338 (or vehicle)
was  administered  by  subcutaneous  osmotic  mini  -
pumps (alzet, cupertino, ca, usa) at a rate of 10
mg/kg*d based on previous experience. the osmotic
minipumps  were  implanted  under  anesthesia  with
isoflurane  4  days  before  the  application  of  galn.
slv338 was released until the end of the experiment.
Baseline  blood  samples  were  taken  in  all  animals 
from the retro-orbital plexus 2 days before the appli-
cation  of  galn.  galn  (or  vehicle)  was  given  twice
(1.3 g/kg) as an intraperitoneal injection at an interval
of 12 hours. Food and water intake were monitored
after the injection of galn. the animals were sacri-
ficed  48  hours  after  the  first  injection  of  galn. 
Blood samples were obtained, liver and kidneys were
excised,  washed  in  ice-cold  saline,  blotted  dry  and
weighed. a slice of the right liver lobe and the right
kidney  were  immediately  frozen  in  liquid  nitrogen.
the remainder of the liver and the left kidney were
fixed in formalin.
PlasMa analysEs
aspartate aminotransferase, alanine aminotransferase,
gamma-glutamyl  transferase  bilirubin,  cholinesterase,
total protein, glucose, creatinine, urea, lipase, creatine
kinase and sodium were measured using an automated
analyzer (cobas Integra 800, Roche, grenzach, ger-
many). Quantification of slv338 plasma concentra-
tions was performed after solid phase extraction using
a validated reversed phase high-pressure liquid chro-
matography method with Ms/Ms detection (sciex api
3000, Perkin Elmer, waltham, Ma, usa).
tIssuE anD PlasMa Et-1 anD BIg-Et-1
tissue  samples  were  prepared  as  described  recently
[13]. Big-Et-1, Et-1 and protein were determined by
a commercially available enzyme immunoassay accord-
ing to the manufacturer’s instructions (Immundiagnos-
tik  ag,  Bensheim,  germany).  Plasma  samples  were
analyzed with the same assays.
HIstology
Formalin-fixed  liver  specimens  were  embedded  in
paraffin,  cut  into  3  ﾵm  sections  and  subjected  to
hematoxylin-eosin staining for morphological evalua-
tion as described previously [3,12]. In brief, histologi-
cal assessment was performed semi-quantitatively in
relation to the extent of necrosis and neutrophil infil-
tration.  a  score  from  0  to  3  was  assigned  to  each
specimen.  necrosis:  0,  normal  histology;  1,  minor
necrosis; 2, widely distributed patchy necrosis of he-
patocytes;  and  3,  complete  lobular  disruption  and 
diffuse  hepatocyte  necrosis.  neutrophil  infiltration: 
0, normal histology; 1, minimal perilobular inflamma-
tory  reaction;  2,  marked  inflammatory  reaction; 
3, panlobular inflammatory reaction. all samples were
evaluated blinded and independently by two investiga-
tors.
statIstIcal analysIs
Data  was  analyzed  with  sPss  17.0  (ssPs  Inc.,
chicago, Il, usa). Results are expressed as mean ﾱ
standard  error  of  the  mean.  the  nonparametric
Mann-whitney u test was used to detect significant
differences between groups of interest. Bivariate cor-
relation was assessed by correlation analysis. Pearson’s
correlation coefficient was used. Mortality was com-
pared using Pearson’s chi-square test.
REsults
Injection  of  galn  resulted  in  severe  liver  injury  re-
flected by strongly elevated plasma liver enzymes and
bilirubin,  reduced  total  plasma  protein  and  glucose
(table 1), histological signs of hepatic necrosis and in-
flammation, reduced food and water intake and a con-
siderable mortality rate of 42.9 % (table 2). there was
no significant change of plasma cholinesterase activity,
probably  because  of its  half-life of  about 14 days.
Base  line plasma values were not different between the
groups (data not shown), except for urea (con 36 ﾱ 3
vs. galn+slv 29 ﾱ 1 mg/dl; p<0.05). Indicators of
renal (creatinine, urea, sodium) and pancreatic function
(lipase) were unaffected by the injection of galn, which
confirms that a selective liver injury had occurred.
Plasma  concentrations  of  slv338  at  study  end
confirm correct drug delivery (table 1). as shown in
tables 1 and 2, treatment with slv338, starting 4 days
before the injection of galn, did not significantly im-
prove any of the mentioned parameters of liver injury.
neither was there a significant reduction of mortality.
slv338 significantly increased food and water intake
in rats with liver injury. However, this effect occurred
in control animals as well (table 2).
at study end, plasma big-Et-1 and Et-1 concentra-
tions were significantly elevated in galn-treated ani-
mals (5-fold and 62-fold, respectively; Fig. 1), as de-
scribed previously [3]. slv338 completely prevented
the rise of plasma big-Et-1 (p<0.05) and markedly at-
tenuated the galn-induced rise of Et-1 (p = 0.055;
Fig. 1). Plasma Et-1 was significantly correlated with
several markers of liver injury as shown in table 3.
this was not the case for plasma big-Et-1. neither
was  there  a  significant  correlation  between  the
slv338 plasma concentrations and markers of liver
injury in the galn+slv group (data not shown). Be-
cause of large inter-individual variations, the ratio of
plasma big-Et-1/Et-1, which is indicative of the con-
version rate of big-Et-1 to Et-1, was not significantly
different between the groups. However, slv338-treat-
ment  more  than  doubled  the  mean  ratio  of  plasma
big-Et-1/Et-1 in rats with liver injury (table 1).
the hepatic Et-1 content was altered neither by the
injection of galn nor by slv338 treatment (table 4).
the renal Et-1 content was significantly decreased in
animals that received galn. slv338 treatment tended
to decrease renal Et-1 concentrations in rats with and
without galn-induced liver injury. Big-Et-1 was low-
est in the galn+slv group (table 4).
livers were slightly lighter in rats with liver injury
compared to controls (table 2). kidney weights were
not different between the groups (data not shown).
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the  present  study  tested  the  hypothesis  that  dual
EcE/nEP blockade might be able to attenuate acute
toxic liver injury in a rat model of galn-induced acute
liver  failure.  Endpoints  of  the  study  were  manifesta-
tions of liver failure such as elevated liver enzymes, he-
patic necrosis and inflammation, and mortality. In addi-
tion, big-Et-1 and Et-1 plasma and tissue concentra-
tions were determined to evaluate the involvement of
the Et system.
treatment with the novel dual EcE/nEP inhibitor
slv338 did not have any significant effect on the extent
of acute liver injury as judged from plasma parameters,
hepatic histology and mortality. this was not due to in-
sufficient  treatment,  since  plasma  measurements  of
slv338 confirmed adequate drug delivery. there was
no toxic effect of slv338, as far as plasma parameters
of liver, kidney, pancreas and muscle are concerned. 
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Table 1. Plasma parameters in rats with D-galactosamine-induced acute liver failure with or without slv338 treatment. 
con con+slv galn galn+slv
n9 9 19 22
aspartate aminotransferase (u/I) 266 ﾱ 27 185 ﾱ 11* 5802 ﾱ 1299** 5743 ﾱ 1217**
alanine aminotransferase (u/I) 46 ﾱ7 40 ﾱ2 2937 ﾱ 700*** 2970 ﾱ 592***
gamma-glutamyl transferase (u/I) 2.0 ﾱ 0.01 4.3 ﾱ2 8.4 ﾱ 2** 9.2 ﾱ 1**
Bilirubin (mg/dl) 0.1 ﾱ 0.01 0.1 ﾱ 0.01 3.2 ﾱ 0.6** 3.7 ﾱ 0.6***
cholinesterase (u/l) 96 ﾱ 14 105 ﾱ 14 94 ﾱ8 87 ﾱ9
total protein (g/dl) 5.0 ﾱ 0.1 5.0 ﾱ 0.1 4.2 ﾱ 0.1*** 4.2 ﾱ 0.2**
glucose (mg/dl) 159 ﾱ7 168 ﾱ7 89 ﾱ 13*** 94 ﾱ 12**
creatinine (mg/dl) 0.27 ﾱ 0.02 0.40 ﾱ 0.13 0.33 ﾱ 0.02 0.35 ﾱ 0.03*
urea (mg/dl) 37 ﾱ3 36 ﾱ6 43 ﾱ2 44 ﾱ5
sodium (mmol/l) 143 ﾱ 0.9 142 ﾱ 0.6 141 ﾱ 0.4 141 ﾱ 0.6
lipase (u/I) 8.3 ﾱ 0.5 9.1 ﾱ 0.2 18.2 ﾱ 7.6 11.0 ﾱ 1.4
creatine kinase (u/I) 1891 ﾱ 169 1135 ﾱ 90** 2687 ﾱ 1483* 866 ﾱ 108***
Big endothelin-1 / Endothelin-1 13.7 ﾱ 7.0 12.5 ﾱ 7.4 8.4 ﾱ 3.5 18.0 ﾱ 14
slv338 (ﾵg/l) 0ﾱ0 703 ﾱ 230 0ﾱ0 545 ﾱ 88
con, controls; slv, slv338; galn, D-galactosamine.
Data are means ﾱ standard error of the mean.
*p<0.05, **p<0.01, ***p<0.001 vs. con.
Table 2. Mortality, weight, food and water intake, liver weight and histology in rats with D-galactosamine-induced acute liver
failure with or without slv338 treatment. 
con con+slv galn galn+slv
n9 9 19 22
Mortality (%) 0042.9 37.1
weight at injection of galn (g) 304 ﾱ7 292 ﾱ3 300 ﾱ4 297 ﾱ3
weight 48 h after galn (g) 298 ﾱ8 298 ﾱ3 280 ﾱ6 283 ﾱ4
Food intake within 48 h after galn (ml) 47 ﾱ 0.2 49 ﾱ 0.5* 20 ﾱ 1.4*** 26 ﾱ 2.0***#
water intake within 48 h after galn (ml) 69 ﾱ 1.9 89 ﾱ 2.8*** 55 ﾱ 2.4** 65 ﾱ 1.2*##
liver weight (g) 10.5 ﾱ 0.4 10.6 ﾱ 0.2 9.5 ﾱ 0.5 8.5 ﾱ 0.4*
liver necrosis score (0-3) 0.61 ﾱ 0.3 0.22 ﾱ 0.1 1.95 ﾱ 0.2** 2.02 ﾱ 0.2**
liver inflammation score (0-3) 0ﾱ0 0ﾱ0 0.97 ﾱ 0.2** 1.09 ﾱ 0.2***
con, controls; slv, slv338; galn, D-galactosamine.
Data are means ﾱ standard error of the mean.
*p<0.05, **p<0.01, ***p<0.001 vs. con.  #p<0.05, ##p<0.01 vs. galn.
Table  3. Bivariate correlation between plasma endothelin-1
and markers of liver injury in all rats that received D-galac-





Food intake within 48 h after galn -0.35*
water intake within 48 h after galn -0.42**
liver necrosis score 0.38*
liver inflammation score 0.35*
galn, D-galactosamine.
Pearson’s  correlation  coefficient  is  given.  only  statistically
significant results are shown. there was no significant corre-
lation between plasma big endothelin-1 and any markers of
liver injury. n = 41. *p<0.05, **p<0.01.
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led to its initial hypothesis. as previously described in
similar models [3-5], the Et system was strongly acti-
vated,  and  a  significant  correlation  between  plasma
Et-1 concentrations and markers of liver damage was
found. this seems to be in line with a previous finding
that exogenous perfusion with Et-1 aggravates acute
liver injury in perfused livers of rats treated with galn
[14]. as hypothesized, the activation of the Et system
was  markedly  reduced  by  slv338  treatment  in  the
present study. It remains unclear why this effect does
not translate into improved clinical outcome. Plasma
parameters, histological alterations and the high mor-
tality within 48 hours after galn administration indi-
cate that the present protocol produced a very severe
form  of  acute  liver  failure.  It  is  conceivable  that
slv338 provides protection against acute liver injury
under less severe conditions. EcE inhibition has for
example been reported to be protective in a rat model
of hepatic ischemia/reperfusion injury which was less
severe, thus allowing a follow-up of 14 days [15].
as described previously [3], the Et system was not
upregulated at the hepatic and renal level in the pre-
sent study. In contrast, Et-1 tissue contents were even
decreased in the kidneys of the animals that received
galn. those findings suggest that the local Et system
of liver and kidneys is not responsible for the strong
increase of plasma Et-1 concentrations. we previous-
ly  speculated  that  an  activated  vascular  Et  system
might  be  the  source  of  the  increased  plasma  Et-1,
since the endothelium is the most probable structure
able to liberate large amounts of Et-1 [3,16]. Howev-
er, the unchanged overall amount of Et-1 in the liver
does  not  exclude  locally  elevated  concentrations  at
crucial localizations, e.g. around the hepatic sinusoids.
In conclusion, slv338 did not significantly attenu-
ate acute toxic liver injury in this very severe rat model
of galn-induced acute liver failure, although it largely
prevented the activation of the Et system. an evalua-
tion of slv338 in a less severe model of liver injury
would  be  of  interest,  since  very  severe  intoxication
might not be relevantly amenable to pharmacological
interventions.
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